FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia

A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement.